These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18193922)

  • 1. Office-based maintenance treatment of opioid dependence: how does it compare with traditional approaches?
    Gunderson EW; Fiellin DA
    CNS Drugs; 2008; 22(2):99-111. PubMed ID: 18193922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients.
    Moore BA; Fiellin DA; Barry DT; Sullivan LE; Chawarski MC; O'Connor PG; Schottenfeld RS
    J Gen Intern Med; 2007 Apr; 22(4):527-30. PubMed ID: 17372805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public sector low threshold office-based buprenorphine treatment: outcomes at year 7.
    Bhatraju EP; Grossman E; Tofighi B; McNeely J; DiRocco D; Flannery M; Garment A; Goldfeld K; Gourevitch MN; Lee JD
    Addict Sci Clin Pract; 2017 Feb; 12(1):7. PubMed ID: 28245872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Very early disengagement and subsequent re-engagement in primary care Office Based Opioid Treatment (OBOT) with buprenorphine.
    Hui D; Weinstein ZM; Cheng DM; Quinn E; Kim H; Labelle C; Samet JH
    J Subst Abuse Treat; 2017 Aug; 79():12-19. PubMed ID: 28673522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series.
    Nielsen S; Bruno R; Degenhardt L; Demirkol A; Lintzeris N
    Drug Alcohol Rev; 2017 May; 36(3):311-316. PubMed ID: 27273511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Office-based opioid dependence treatment.
    Colson J; Helm S; Silverman SM
    Pain Physician; 2012 Jul; 15(3 Suppl):ES231-6. PubMed ID: 22786460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
    Sullivan LE; Chawarski M; O'Connor PG; Schottenfeld RS; Fiellin DA
    Drug Alcohol Depend; 2005 Jul; 79(1):113-6. PubMed ID: 15943950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term retention in Office Based Opioid Treatment with buprenorphine.
    Weinstein ZM; Kim HW; Cheng DM; Quinn E; Hui D; Labelle CT; Drainoni ML; Bachman SS; Samet JH
    J Subst Abuse Treat; 2017 Mar; 74():65-70. PubMed ID: 28132702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.
    LaBelle CT; Han SC; Bergeron A; Samet JH
    J Subst Abuse Treat; 2016 Jan; 60():6-13. PubMed ID: 26233698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Office-Based Buprenorphine Versus Clinic-Based Methadone: A Cost-Effectiveness Analysis.
    King JB; Sainski-Nguyen AM; Bellows BK
    J Pain Palliat Care Pharmacother; 2016; 30(1):55-65. PubMed ID: 27007583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of opioid dependence in the setting of pregnancy.
    Young JL; Martin PR
    Psychiatr Clin North Am; 2012 Jun; 35(2):441-60. PubMed ID: 22640765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial sustainability of payment models for office-based opioid treatment in outpatient clinics.
    Hodgkin D; Horgan C; Bart G
    Addict Sci Clin Pract; 2021 Jul; 16(1):45. PubMed ID: 34225785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating opioid dependence. Growing implications for primary care.
    Krantz MJ; Mehler PS
    Arch Intern Med; 2004 Feb; 164(3):277-88. PubMed ID: 14769623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Public policy statement on Office-Based Opioid Agonist Treatment (OBOT).
    J Addict Dis; 2005; 24(3):153-61. PubMed ID: 16186090
    [No Abstract]   [Full Text] [Related]  

  • 16. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
    Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
    J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.
    Moody DE
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):675-97. PubMed ID: 23537174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opioid dependence treatment and guidelines.
    Nicholls L; Bragaw L; Ruetsch C
    J Manag Care Pharm; 2010 Feb; 16(1 Suppl B):S14-21. PubMed ID: 20146550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.
    Kraus ML; Alford DP; Kotz MM; Levounis P; Mandell TW; Meyer M; Salsitz EA; Wetterau N; Wyatt SA;
    J Addict Med; 2011 Dec; 5(4):254-63. PubMed ID: 22042215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methadone versus buprenorphine for the treatment of opioid abuse in pregnancy: science and stigma.
    Holbrook AM
    Am J Drug Alcohol Abuse; 2015; 41(5):371-3. PubMed ID: 26154531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.